During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.
Merck announced yesterday that new combination and monotherapy data from the company’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.
Meeting combined exercise guidelines – including both aerobics and strength training – improved quality of life in #KidneyCancer survivors; however, few individuals reported they follow such guidelines, according to study findings published in Psycho-Oncology.
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.
Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.
This article explains how to support a loved one after cancer treatment.
Gretchen Vaughan, Kidney Cancer Association, has been named chief executive officer of the nonprofit.
Kidney cancer had the sharpest annual increase for young Americans: 6.23% between 1995 and 2014.